OTCMKTS:AOLS - Aeolus Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.0052 +0.00 (+13.04 %)
(As of 07/18/2018 05:04 AM ET)
Previous Close$0.0046
Today's Range$0.0052 - $0.0052
52-Week Range$0.0010 - $0.11
Volume40,000 shs
Average Volume10,606 shs
Market Capitalization$700,000.00
P/E RatioN/A
Dividend YieldN/A
Beta2.22
Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

Receive AOLS News and Ratings via Email

Sign-up to receive the latest news and ratings for AOLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:AOLS
CUSIPN/A
Phone949-481-9825

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.08 million
Price / Sales0.38
Cash FlowN/A
Price / CashN/A
Book Value$0.02 per share
Price / Book0.26

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares152,090,000
Market Cap$0.70

The Truth About Cryptocurrencies

Aeolus Pharmaceuticals (OTCMKTS:AOLS) Frequently Asked Questions

What is Aeolus Pharmaceuticals' stock symbol?

Aeolus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "AOLS."

How were Aeolus Pharmaceuticals' earnings last quarter?

Aeolus Pharmaceuticals, Inc. (OTCMKTS:AOLS) announced its quarterly earnings data on Monday, August, 14th. The biopharmaceutical company reported ($0.01) EPS for the quarter. The biopharmaceutical company had revenue of $0.01 million for the quarter. View Aeolus Pharmaceuticals' Earnings History.

When is Aeolus Pharmaceuticals' next earnings date?

Aeolus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Aeolus Pharmaceuticals.

What is the consensus analysts' recommendation for Aeolus Pharmaceuticals?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeolus Pharmaceuticals in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Aeolus Pharmaceuticals' key competitors?

Who are Aeolus Pharmaceuticals' key executives?

Aeolus Pharmaceuticals' management team includes the folowing people:
  • Mr. David C. Cavalier, Chairman, CFO & Sec. (Age 49)
  • Mr. John L. McManus, CEO & Pres (Age 54)
  • Mr. Christopher Stanley, VP of Operations
  • Dr. Brian J. Day Ph.D., Chief Scientific Officer (Age 58)

Has Aeolus Pharmaceuticals been receiving favorable news coverage?

News headlines about AOLS stock have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aeolus Pharmaceuticals earned a daily sentiment score of 0.08 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.31 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Aeolus Pharmaceuticals?

Shares of AOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aeolus Pharmaceuticals' stock price today?

One share of AOLS stock can currently be purchased for approximately $0.0052.

How big of a company is Aeolus Pharmaceuticals?

Aeolus Pharmaceuticals has a market capitalization of $700,000.00 and generates $2.08 million in revenue each year.

How can I contact Aeolus Pharmaceuticals?

Aeolus Pharmaceuticals' mailing address is 26361 CROWN VALLEY PARKWAY SUITE 150, MISSION VIEJO CA, 92691. The biopharmaceutical company can be reached via phone at 949-481-9825 or via email at [email protected]


MarketBeat Community Rating for Aeolus Pharmaceuticals (OTCMKTS AOLS)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  38 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  99
MarketBeat's community ratings are surveys of what our community members think about Aeolus Pharmaceuticals and other stocks. Vote "Outperform" if you believe AOLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AOLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.